CasNo.82640-04-8,99% Raloxifen HCl Powder cas 82640-04-8,(82640-04-8) Suppliers

1 Gram	FOB Price:USD 95.0000 -100.0000

Min.Order :1 Gram
Purity: 99%
Payment Terms : T/T,

Keywords

Raloxifen HCl 82640-04-8 CAS 82640-04-8

Quick Details

Appearance:white powder
Application:Animal Pharmaceuticals
PackAge:carton boc
ProductionCapacity:1000000|Kilogram|Month
Storage:cool and dry
Transportation:ship,fly

Superiority:

Hebei Mojin Biotechnology Co., Ltd,Our business covers more than 30 countries, most of the big customers come from Europe, America and other countries in the world, we can guarantee the quality and price. In recent decades, with the efforts of all employees, we have established many cooperative companies in shandong, henan, guangdong and other places. Our corporate purpose is based on the market, enhance the strength, take the road of scientific and environmental sustainable development, relying on the country. Technology r & d center, increase the investment in r & d, based on the domestic market, expand the international market, manufacturing quality products, sincere service to the society, into a modern, ecological, scientific and technological enterprise world.

Adenosine triphosphate can be used in the disease caused by tissue injury and activity reduction of ecto enzyme , including heart failure, carditis, miocardial infarction, cerebral arteriosclersis, coronary sclerosis, progressive muscular atrophy , cerebral hemorrhage , chronic hepatitis, cirrhosis of liver and hearing handicap, etc.

Details:

Product Detailed

Product Name	Raloxifen e Hydrochloride
CAS NO.	82640-04-8
Other Name	Raloxifen e HCl
Molecular Formular	C₂₈H₂₈ClNO₄S
Molecular Weight	510.044
Appearance	LIGHT YELLOW powder
Purity	99%
Boiling Point	728.2ºC at 760 mmHg
Meliting Point	143-147ºC
Flash Point	394.2ºC
Density	1.285g/cm3

R'aloxifene Hydrochloride is an estrogen agonist/antagonist, referred to as a selective estrogen receptor modulator (SERM) and belongs to the benzothiophe class of compounds. The biological actions of R'aloxifene are largely mediated through binding to estrogen receptors. This binding results in activation of estrogenic pathways in some tissues (Agonism) and and the blockade of estrogenic pathways in other tissues (Antagonism).

Product Parameters

ITEMS	SPECIFICATION		RESULT
Appearance	Light Yellow Powder		Conform
Solubility	Soluble in 10% sodium hydroxid solution. Slightly Soluble in meth anol. Insoluble in water		Conform
Identifications	Infrared Absorption		Conform
	Chloride		Conform
Tests	Loss on drying	≤0.5%	0.4%
	Residue on ignition	≤0.1%	0.06%
	Heavy metals	≤10ppm	Conform
Related substances	R'aloxifene Impurity1	≤0.20 %	0.10%
	Any unspecified individual impurity 2	≤0.10%	Max. 0.08%
	Total impurities	≤0.50%	0.40%
Assay	R'aloxifene HCl	≥98.0%	99.0%

Product Usage

(1) R'aloxifene is used to prevent and treat osteoporosis (condition in which the bones become thin and weak and break easily) in women who have undergone menopause (change of life; end of menstrual periods). R'aloxifene is also used to decrease the risk of developing invasive breast cancer (breast cancer that has spread outside of the milk ducts or lobules into the surrounding breast tissue) in women who are at high risk of developing this type of cancer or who have osteoporosis. R'aloxifene cannot be used to treat invasive breast cancer or to prevent invasive breast cancer from coming back in women who have already had the condition.

(2) R'aloxifene also cannot be used to decrease the risk of developing non-invasive breast cancer. R'aloxifene is in a class of medications called selective estrogen receptor modulators (SERMs). R'aloxifene prevents and treats osteoporosis by mimicking the effects of estrogen (a female hormone produced by the body) to increase the density (thickness) of bone. R'aloxifene decreases the risk of developing invasive breast cancer by blocking the effects of estrogen on breast tissue. This may stop the development of tumors that need estrogen to grow.